Revenio Group Oyj - Total number of voting rights and capital

Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, May 24, 2016 at 9:00

INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER

25,263 new share subscriptions based on the company's 2007C stock options
approved by the Board of Directors of Revenio Group Corporation on May 9, 2016,
have been entered into the trade register today. The share subscription price
under 2007C option rights was 0.54 EUR per share. The subscription period for
2007C options was until May 1, 2016.

After these subscriptions, the number of Revenio Group Corporation's shares and
votes will rise to 7,979,406. These increases were recorded in their entirety in
the unrestricted shareholders' equity fund.

Revenio Group Corporation has applied for the listing of its new shares on the
Nasdaq Helsinki in the same series as the company's existing shares. According
to the current estimate, the new shares will be listed on May 25, 2016.

Revenio Group Oyj
Olli-Pekka Salovaara
CEO


For further information, please contact:

President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims at developing
even more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating
margin for continuing operations standing at 28.4%. Revenio Group Corporation is
listed on Nasdaq Helsinki.

[HUG#2013607]